Abstract: The present application relates to novel tetrahydrobenzo[d]azepin-2-one derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidaemias, arteriosclerosis, restenosis and ischaemias.
Type:
Grant
Filed:
February 1, 2005
Date of Patent:
February 16, 2010
Assignee:
Bayer Shering Pharma AG
Inventors:
Nils Griebenow, Timo Flessner, Michael Härter, Martin Raabe, Anja Buchmüller, Hilmar Bischoff, Peter Ellinghaus, Peter Kolkhof
Abstract: The invention provides isolated nucleic acids molecules, designated TWIK nucleic acid molecules, which encode proteins involved in potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TWIK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TWIK gene has been introduced or disrupted. The invention still further provides isolated TWIK proteins, fusion proteins, antigenic peptides and anti-TWIK antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Type:
Grant
Filed:
November 4, 2003
Date of Patent:
April 14, 2009
Assignee:
Bayer Shering Pharma AG
Inventors:
Rory A. J. Curtis, Inmaculada Silos-Santiago